


Copper-Catalyzed C–N Bond Formation/Rearrangement Sequence: Synthesis of 4*H*-3,1-Benzoxazin-4-ones

Zhi-Yuan Ge,[†] Qiong-Ming Xu,[†] Xiang-Dong Fei,[†] Ting Tang,[†] Yong-Ming Zhu,^{*,†} and Shun-Jun Ji[‡]

[†]College of Pharmaceutical Sciences and [‡]College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, People's Republic of China

Supporting Information



ABSTRACT: A facile and efficient copper-catalyzed method for the synthesis of 4*H*-3,1-benzoxazin-4-one derivatives has been developed. This procedure is based on a tandem intramolecular C–N coupling/rearrangement process. This method would provide a new and useful strategy for construction of N-heterocycles.

INTRODUCTION

4*H*-3,1-Benzoxazin-4-ones are a class of fused heterocycles that are of interest to organic chemists owing to their biological activities.^{1–8} For instance, some of the 2-substituted 4*H*-3,1-benzoxazin-4-ones act as chymotrypsin inactivators (I),¹ HSV-1 protease inhibitors (II),² and inhibitors of human leukocyte elastase (III),³ cathepsin G,⁴ C1r serine protease,⁵ and human chymase.⁶ In addition, compound IV, shown in Figure 1, has




Figure 1. Structures of some bioactive 2-substituted 4*H*-3,1-benzoxazin-4-ones.

the ability to lower the level of plasma cholesterol and triglyceride.⁷ Moreover, cetilistat (V), a novel lipase inhibitor, was reported to be used as an antiobesity remedy.⁸ In addition, 2-substituted 4*H*-3,1-benzoxazin-4-ones are useful synthetic intermediates for the synthesis of pharmaceutically active compounds.⁹ Therefore, it is not surprising that there is an ever-increasing number of synthetic approaches toward the preparation of 4*H*-3,1-benzoxazin-4-one derivatives, especially 4*H*-3,1-benzoxazin-4-ones substituted in the 2-position.^{10–17} Among these methodologies, cyclization of anthranilic acid or *N*-acylanthranilic acid and ring transformation of isatoic

anhydride are most popular.¹¹ Other notable methods include oxidation of 2-aryl-3*H*-indol-3-ones, 2-phenyl-3-oxo-3*H*-indole 1-oxide, or 2-aryl-4*H*-benzo[*d*][1,3]oxazines,¹² thermolysis of benzo[*d*][1,2,3]triazin-4(3*H*)-ones or isatoic anhydride,¹³ electrochemical cyclization of *o*-trichloroacetyl-anilides,¹⁴ cyclization of 2-ureidobenzoic acids, alkyl 2-ureidobenzoates, or 2-ureidobenzamides,¹⁵ palladium-catalyzed carbonylation with CO,¹⁶ and palladium-catalyzed cyclization of azidoalkynes.¹⁷ Some of these methods still suffer from either harsh reaction conditions or hazardous materials. Consequently, we are making an effort to investigate a further efficient method for the synthesis of this class of N-heterocycles.


Very recently, our group reported a novel copper(I)-catalyzed reaction of 1-(2-halophenyl)-1,3-diones,¹⁸ which involves a rearrangement process as a key step. We hypothesized that the similar strategy might be applicable to prepare benzoxazinones from *N*-acyl-2-halobenzamides. In a continuation to our interest in copper-catalyzed tandem cyclization reactions, herein, we would like to report a new strategy for the synthesis of 2-substituted benzoxazinones via a copper-catalyzed reaction of *N*-acyl-2-halobenzamides.

RESULTS AND DISCUSSION

We initially investigated the reaction conditions by employing *N*-phenyl-2-iodobenzamide (1a) as the model substrate (Table 1). Considering that 2-picolinic acid was used as the best ligand of CuI in our previous study,¹⁸ we tested the reaction in the presence of CuI (10 mol %), 2-picolinic acid (20 mol %), and K₂CO₃ (2 equiv) in anhydrous toluene (5 mL) at 120 °C, and a 42% yield of the desired product was obtained after 6 h (Table 1, entry 1). Then, several ligands and a ligand-free condition were tested in this reaction, and a comparable yield was obtained in the absence of ligand (Table 1, entries 2–4). Base

Received: March 11, 2013

Published: April 12, 2013

Table 1. Optimizations of Conditions for Benzoxazinone Synthesis^a

| entry | catalyst | ligand ^b | base | solvent ^c | additive | yield ^d (%) |
|-------|----------------------|---------------------|---------------------------------|----------------------|-------------------|------------------------|
| 1 | CuI | L1 | K ₂ CO ₃ | toluene | | 42 |
| 2 | CuI | L2 | K ₂ CO ₃ | toluene | | 36 |
| 3 | CuI | L3 | K ₂ CO ₃ | toluene | | 38 |
| 4 | CuI | | K ₂ CO ₃ | toluene | | 42 |
| 5 | CuI | | Cs ₂ CO ₃ | toluene | | 35 |
| 6 | CuI | | NaOtBu | toluene | | 0 |
| 7 | CuI | | NaOAc | toluene | | 0 |
| 8 | CuI | | KF | toluene | | 25 |
| 9 | CuI | | K ₃ PO ₄ | toluene | | 60 |
| 10 | CuI | | K ₃ PO ₄ | toluene | MS 4 Å | 63 |
| 11 | CuI | | K ₃ PO ₄ | toluene | MgSO ₄ | 69 |
| 12 | CuI | | K ₃ PO ₄ | toluene | CaO | 65 |
| 13 | CuI | | K ₃ PO ₄ | toluene | CaCl ₂ | 81 |
| 14 | CuI | | K ₃ PO ₄ | <i>o</i> -xylene | CaCl ₂ | 75 |
| 15 | CuI | | K ₃ PO ₄ | 1,4-dioxane | CaCl ₂ | 65 |
| 16 | CuI | | K ₃ PO ₄ | THF | CaCl ₂ | 58 |
| 17 | CuBr | | K ₃ PO ₄ | toluene | CaCl ₂ | 73 |
| 18 | CuCl | | K ₃ PO ₄ | toluene | CaCl ₂ | 71 |
| 19 | Cu(OAc) ₂ | | K ₃ PO ₄ | toluene | CaCl ₂ | 70 |

^aAll reactions were run with **1a** (0.5 mmol), catalyst (0.05 mmol), ligand (0.1 mmol), base (1.0 mmol), additive (1.0 mmol), and solvent (5 mL) under nitrogen in a sealed tube for 6 h. ^bL1: 2-picolinic acid. L2: (±)-trans-1,2-diaminocyclohexane. L3: 1,10-phenanthroline. ^cReaction temperature: 1,4-dioxane and toluene were at 120 °C, *o*-xylene was at 150 °C, and THF was at 70 °C. ^dIsolated yield.

screening tests revealed that K₃PO₄ in comparison with other bases, produced **2a** by the yield increased to 60% (Table 1, entries 5–9). Analytical results showed that benzoic acid was a major byproduct. Considering that adventitious moisture might result in the generation of benzoic acid in the reaction, we tested several drying agents, and a 81% yield was obtained in the presence of CaCl₂ (Table 1, entries 10–13). Other solvents, such as *o*-xylene, 1,4-dioxane, and THF, proved to be less effective (Table 1, entries 14–16). A comparison of catalysts showed that CuI was superior to the others (Table 1, entries 17–19). Based on these considerations, our products could be easily obtained from **1a** in the presence of CuI (10 mol %), K₃PO₄ (2 equiv), and CaCl₂ (2 equiv) in anhydrous toluene (5 mL) within a sealed tube under nitrogen at 120 °C for 6 h.

To evaluate the scope and generality of the methodology, different substrates with varying substituents were synthesized and investigated under the standard reaction conditions, and the results are summarized in Tables 2 and 3. Substrates bearing both electron-rich and electron-poor aromatic groups on R² generated the desired products in moderate to good yields (**2b–h**). Similar results were obtained when R² was furanyl (**2i** and **2j**), and a lower yield was observed when it was thiophene-2-yl (**2k**). The reaction proceeded smoothly to give the desired products in moderate yields, as for a variety of substrates with alkyl and alkenyl substituents on R² (**2l–o**). It was also of note that electronic properties of R¹ had no

significant effect on this reaction, and desired products were obtained in good yields (**2p–t**).

As illustrated in Table 3, when the substrate was changed from iodoarene to bromoarene, a slightly lower yield was observed (**2a**). Various substituted *N*-benzoyl-2-bromobenzamides were also examined, and the target products were produced in moderate yields (**2u–y**). We found that **2y** was generated in a good yield when 1-(1-bromonaphthalen-2-yl) was the substituent on substrate **1y** probably owing to the weak aromaticity of the naphthalene ring.

On the basis of the above experimental results and related reports,^{13c,18} a plausible mechanism for this reaction was depicted in Scheme 1. Copper iodide would activate *N*-benzoyl-2-iodobenzamide (**1a**) to generate a copper(I) complex **A**, which would then produce *N*-benzoyl benzazetonone (**B**) via the C–N coupling process. Immediately, release of ring strain led to the ketene compound **C** via the C–N bond cleavage. Ring closure of **C** would then yield the target product **2a**.

CONCLUSION

In summary, we have developed an efficient and rapid method for the synthesis of 4*H*-3,1-benzoxazin-4-one derivatives from easily available *N*-acyl-2-halobenzamides. The key step of this transformation is the C–N bond formation/rearrangement sequence. Considering mild reaction conditions and a wide functional-group tolerance, this protocol is expected to be beneficial to organic synthesis.


EXPERIMENTAL SECTION

General Remarks. Chemicals and reagents were purchased from commercial suppliers and used without special instructions. All anhydrous solvents used in the reactions were dried and freshly distilled. Thin-layer chromatography (TLC) was performed using silica HSGF254 plates. Melting points were determined without correction on a digital melting-point apparatus. ¹H and ¹³C NMR spectra were obtained from a solution in CDCl₃ with tetramethylsilane (TMS) as internal standard using a 400/101 MHz (¹H/¹³C) or 300/75 MHz (¹H/¹³C) spectrometer, δ in parts per million (ppm), and *J* in hertz (Hz). Infrared (IR) spectra were recorded in KBr tablets, and wavenumbers in cm⁻¹; HRMS analyses were carried out on an electrospray ionization (ESI) apparatus using time-of-flight (TOF) mass spectrometry.

General Procedure for the Synthesis of Compounds 2a–y. A sealed tube was charged with a magnetic stir bar, substrate **1** (0.5 mmol),¹⁹ CuI (0.05 mmol, 10 mg), K₃PO₄ (1.0 mmol, 212 mg), CaCl₂ (1.0 mmol, 111 mg), and anhydrous toluene (5 mL). The tube was purged with nitrogen gas and stirred at 120 °C for the indicated time. After completion of reaction, the mixture was filtered through a short plug of Celite, and washed with EtOAc (2 × 3 mL). The combined filtrates were concentrated on a rotary evaporator and purified on a silica gel column using petroleum ether/EtOAc as eluent to give the pure target product.

Characterization Data of the Isolated Compounds. *2-Phenyl-4*H*-3,1-benzoxazin-4-one (2a)*.¹⁷ From substrate *N*-benzoyl-2-iodobenzamide, yield 78% (87 mg); from substrate *N*-benzoyl-2-bromobenzamide, yield 65% (73 mg): white solid; mp 108–110 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.30–8.28 (m, 2H), 8.22 (d, *J* = 7.7 Hz, 1H), 7.81 (t, *J* = 7.4 Hz, 1H), 7.67 (d, *J* = 7.9 Hz, 1H), 7.58–7.55 (m, 1H), 7.52–7.48 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 159.7, 157.2, 147.1, 136.7, 132.7, 130.3, 128.8, 128.7, 128.4, 128.4, 127.3, 117.1; IR (KBr) ν = 1764, 1617, 1472, 1316, 1259, 1062, 1009, 762, 682, 629 cm⁻¹; LRMS (ESI) *m/z* calcd for C₁₄H₁₀N₂O₂ [M + H]⁺ 224.1, found 224.1.

*2-*p*-Tolyl-4*H*-3,1-benzoxazin-4-one (2b)*.¹⁷ yield 90% (107 mg); white solid; mp 138–140 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.23–8.18 (m, 3H), 7.81 (t, *J* = 7.3 Hz, 1H), 7.66 (d, *J* = 8.0 Hz, 1H), 7.49

Table 2. Copper-Catalyzed Reaction of Substituted *N*-Acyl-2-iodobenzamide^a

^aThe reactions were performed in a sealed tube with **1** (0.5 mmol), CuI (0.05 mmol), K₃PO₄ (1.0 mmol), and CaCl₂ (1.0 mmol) in toluene (5 mL) at 120 °C under nitrogen for 6 h. ^bIsolated yield. ^c80% conversion, 140 °C, 48 h. ^d140 °C, 20 h.

(*t*, *J* = 7.4 Hz, 1H), 7.30 (*d*, *J* = 7.7 Hz, 2H), 2.43 (*s*, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 159.8, 157.4, 147.2, 143.5, 136.6, 129.6, 128.7, 128.4, 128.1, 127.5, 127.2, 117.0, 21.8; LRMS (ESI) *m/z* calcd for C₁₅H₁₂NO₂ [M + H]⁺ 238.1, found 238.1.


2-(4-Methoxyphenyl)-4*H*-3,1-benzoxazin-4-one (**2c**):¹⁷ yield 83% (105 mg); white solid; mp 144–145 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.19 (*t*, *J* = 9.0 Hz, 3H), 7.76 (*t*, *J* = 7.7 Hz, 1H), 7.60 (*d*, *J* = 8.0 Hz, 1H), 7.44 (*t*, *J* = 7.5 Hz, 1H), 6.95 (*d*, *J* = 8.7 Hz, 2H), 3.86 (*s*, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.3, 159.8, 157.1, 147.4, 136.5, 130.3, 128.6, 127.7, 127.0, 122.5, 116.7, 114.2, 55.5; LRMS (ESI) *m/z* calcd for C₁₃H₁₂NO₃ [M + H]⁺ 254.1, found 254.1.

2-(3,4,5-Trimethoxyphenyl)-4*H*-3,1-benzoxazin-4-one (**2d**):^{11d} yield 84% (132 mg); white solid; mp 179–181 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.20 (*d*, *J* = 7.7 Hz, 1H), 7.80 (*t*, *J* = 7.4 Hz, 1H), 7.65 (*d*, *J* = 7.9 Hz, 1H), 7.55–7.46 (*m*, 3H), 3.98 (*s*, 6H), 3.95 (*s*, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 159.6, 156.7, 153.2, 147.0, 142.0,

136.6, 128.6, 128.1, 127.0, 125.2, 116.7, 105.4, 61.0, 56.4; LRMS (ESI) *m/z* calcd for C₁₇H₁₆NO₅ [M + H]⁺ 314.1, found 314.1.

2-(4-Fluorophenyl)-4*H*-3,1-benzoxazin-4-one (**2e**):^{12d} yield 77% (93 mg); white solid; mp 176–177 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.30 (*dd*, *J* = 8.1, 5.7 Hz, 2H), 8.22 (*d*, *J* = 7.7 Hz, 1H), 7.82 (*t*, *J* = 7.5 Hz, 1H), 7.66 (*d*, *J* = 8.1 Hz, 1H), 7.51 (*t*, *J* = 7.5 Hz, 1H), 7.18 (*t*, *J* = 8.5 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 167.3, 163.9, 159.4, 156.2, 146.9, 136.6, 130.8, 130.7, 128.6, 128.3, 127.2, 126.4, 126.4, 116.8, 116.2, 115.9; LRMS (ESI) *m/z* calcd for C₁₄H₉FNO₂ [M + H]⁺ 242.1, found 242.1.

2-(4-(Trifluoromethyl)phenyl)-4*H*-3,1-benzoxazin-4-one (**2f**):^{16h} yield 60% (87 mg); white solid; mp 127–128 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.57 (*s*, 1H), 8.48 (*d*, *J* = 7.7 Hz, 1H), 8.24 (*d*, *J* = 7.7 Hz, 1H), 7.87–7.81 (*m*, 2H), 7.71 (*d*, *J* = 8.0 Hz, 1H), 7.65 (*t*, *J* = 7.7 Hz, 1H), 7.55 (*t*, *J* = 7.4 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 159.2, 155.7, 147.4, 146.6, 136.9, 131.7, 131.4, 131.3, 131.2, 129.5,

Table 3. Copper-Catalyzed Reaction of Substituted *N*-Benzoyl-2-bromobenzamide^a

^aThe reactions were performed in a sealed tube with 1 (0.5 mmol), CuI (0.05 mmol), K₃PO₄ (1.0 mmol), and CaCl₂ (1.0 mmol) in toluene (5 mL) at 120 °C under nitrogen for 6 h. ^bIsolated yield.

129.1, 129.1, 128.9, 128.8, 127.5, 125.3, 125.3, 122.0, 120.0, 117.1, 112.8, 112.4; LRMS (ESI) *m/z* calcd for C₁₃H₉F₃NO₂ [M + H]⁺ 292.1, found 292.1.

2-(2-Chlorophenyl)-4*H*-3,1-benzoxazin-4-one (2g):^{17c} yield 53% (68 mg); white solid; mp 135–137 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.25 (d, *J* = 7.7 Hz, 1H), 7.90 (d, *J* = 7.5 Hz, 1H), 7.85 (t, *J* = 7.6 Hz, 1H), 7.71 (d, *J* = 8.0 Hz, 1H), 7.57 (t, *J* = 7.5 Hz, 1H), 7.52 (d, *J* = 7.8 Hz, 1H), 7.46 (t, *J* = 7.4 Hz, 1H), 7.40 (t, *J* = 7.3 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 159.2, 156.5, 146.4, 136.7, 133.4, 132.4, 131.5, 131.1, 130.3, 129.0, 128.6, 127.4, 127.0, 117.0; LRMS (ESI) *m/z* calcd for C₁₄H₉ClNO₂ [M + H]⁺ 258.0, found 258.0.

2-(Naphthalen-1-yl)-4*H*-3,1-benzoxazin-4-one (2h):^{17e} yield 70% (96 mg); yellow solid; mp 118–120 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.14 (d, *J* = 8.6 Hz, 1H), 8.30–8.24 (m, 2H), 8.01 (d, *J* = 8.1 Hz, 1H), 7.89 (d, *J* = 8.0 Hz, 1H), 7.82 (t, *J* = 7.5 Hz, 1H), 7.75 (d, *J* = 7.9 Hz, 1H), 7.63 (t, *J* = 7.6 Hz, 1H), 7.56–7.50 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 159.7, 157.6, 146.8, 136.6, 134.1, 133.3, 130.8, 130.1, 128.9, 128.6, 128.5, 127.9, 127.4, 126.9, 126.4, 125.8, 124.8, 117.0; LRMS (ESI) *m/z* calcd for C₁₈H₁₂NO₂ [M + H]⁺ 274.1, found 274.1.

2-(Furan-2-yl)-4*H*-3,1-benzoxazin-4-one (2i):^{10a} yield 64% (68 mg); yellow solid; mp 95–96 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, *J* = 7.6 Hz, 1H), 7.80 (t, *J* = 7.4 Hz, 1H), 7.72–7.67 (m, 2H), 7.49 (t, *J* = 7.3 Hz, 1H), 7.37–7.33 (m, 1H), 6.61 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 158.6, 149.8, 147.1, 146.7, 144.4, 136.8, 128.8, 128.3,

127.2, 117.2, 116.9, 112.6; LRMS (ESI) *m/z* calcd for C₁₂H₈NO₃ [M + H]⁺ 214.0, found 214.0.

2-(Furan-3-yl)-4*H*-3,1-benzoxazin-4-one (2j): yield 59% (63 mg); white solid; mp 71–73 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.21–8.10 (m, 2H), 7.76 (t, *J* = 7.6 Hz, 1H), 7.56 (d, *J* = 8.0 Hz, 1H), 7.50 (s, 1H), 7.45 (t, *J* = 7.5 Hz, 1H), 6.95 (s, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 159.1, 153.3, 146.8, 146.4, 144.4, 136.5, 128.5, 128.0, 126.7, 119.7, 116.9, 109.0; IR (KBr) ν = 1766, 1635, 1604, 1397, 1163, 1006, 875, 769, 688, 595 cm⁻¹; HRMS (ESI) *m/z* calcd for C₁₂H₇NNaO₃ [M + Na]⁺ 236.0318, found 236.0318.

2-(Thiophene-2-yl)-4*H*-3,1-benzoxazin-4-one (2k): yield 36% (41 mg); white solid; mp 124–126 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, *J* = 7.8 Hz, 1H), 7.98–7.96 (m, 1H), 7.81 (t, *J* = 7.6 Hz, 1H), 7.65–7.61 (m, 2H), 7.49 (t, *J* = 7.5 Hz, 1H), 7.18 (t, *J* = 3.9 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 159.2, 153.9, 147.2, 136.8, 134.3, 132.6, 132.0, 128.9, 128.5, 128.1, 127.0, 116.8; HRMS (ESI) *m/z* calcd for C₁₂H₈NO₂S [M + H]⁺ 230.0270, found 230.0270.


2-*tert*-Butyl-4*H*-3,1-benzoxazin-4-one (2l):¹⁷ yield 42% (43 mg); white solid; mp 124–125 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, *J* = 7.7 Hz, 1H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.60 (d, *J* = 8.0 Hz, 1H), 7.50 (t, *J* = 7.5 Hz, 1H), 1.41 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 168.4, 160.4, 146.7, 136.5, 128.4, 128.2, 127.1, 116.9, 38.1, 27.8; LRMS (ESI) *m/z* calcd for C₁₂H₁₄NO₂ [M + H]⁺ 204.1, found 204.1.

2-Adamantyl-4*H*-3,1-benzoxazin-4-one (2m): yield 61% (86 mg); white solid; mp 94–96 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 7.7 Hz, 1H), 7.78 (t, *J* = 7.4 Hz, 1H), 7.59 (d, *J* = 8.0 Hz, 1H), 7.48 (t, *J* = 7.5 Hz, 1H), 2.11 (s, 3H), 2.08 (s, 6H), 1.82–1.74 (m, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 167.8, 160.4, 146.8, 136.4, 128.4, 128.1, 127.0, 117.1, 39.8, 39.4, 36.5, 28.0; IR (KBr) ν = 2904, 2850, 1756, 1632, 1606, 1451, 1210, 1037, 1003, 765, 685, 620 cm⁻¹; HRMS (ESI) *m/z* calcd for C₁₈H₁₉NNaO₂ [M + Na]⁺ 304.1308, found 304.1321.

(*E*)-2-Styryl-4*H*-3,1-benzoxazin-4-one (2n):^{16c} yield 67% (84 mg); white solid; mp 144–146 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.16 (d, *J* = 7.7 Hz, 1H), 7.80–7.73 (m, 2H), 7.57–7.53 (m, 3H), 7.44 (t, *J* = 7.4 Hz, 1H), 7.40–7.33 (m, 3H), 6.73 (d, *J* = 16.1 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 159.2, 157.2, 147.0, 141.9, 136.5, 134.6, 130.3, 129.0, 128.6, 128.1, 128.0, 126.9, 118.8, 116.9; LRMS (ESI) *m/z* calcd for C₁₆H₁₂NO₂ [M + H]⁺ 250.1, found 250.1.

2-(*Prop-1-en-2-yl*)-4*H*-3,1-benzoxazin-4-one (2o): yield 53% (50 mg); white solid; mp 92–93 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.24–8.18 (m, 1H), 7.83–7.76 (m, 1H), 7.67–7.60 (m, 1H), 7.54–7.47 (m, 1H), 6.35 (s, 1H), 5.71 (s, 1H), 2.17 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 159.6, 157.5, 146.8, 136.5, 135.8, 128.6, 128.5, 127.5, 124.3, 117.2, 18.9; HRMS (ESI) *m/z* calcd for C₁₁H₁₀NO₂ [M + H]⁺ 188.0706, found 188.0704.

7-Chloro-2-phenyl-4*H*-3,1-benzoxazin-4-one (2p):^{17g} yield 75% (97 mg); white solid; mp 180–182 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.32–8.26 (m, 2H), 8.16 (d, *J* = 8.3 Hz, 1H), 7.69 (s, 1H), 7.63–7.56 (m, 1H), 7.56–7.40 (m, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 158.9, 158.4, 148.2, 143.1, 133.2, 130.0, 129.9, 128.9, 128.9, 128.6,

Scheme 1. Postulated Reaction Mechanism

127.1, 115.5; LRMS (ESI) m/z calcd for $C_{14}H_9ClNO_2$ $[M + H]^+$ 258.0, found 258.0.

6-Chloro-2-phenyl-4H-3,1-benzoxazin-4-one (2q):¹⁷ yield 87% (112 mg); white solid; mp 152–153 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 8.31–8.26 (m, 1H), 8.26–8.24 (m, 1H), 8.16 (d, $J = 2.4$ Hz, 1H), 7.73 (dd, $J = 8.6, 2.4$ Hz, 1H), 7.64–7.54 (m, 2H), 7.50 (m, 2H); ¹³C NMR (101 MHz, $CDCl_3$) δ 158.5, 157.4, 145.6, 136.9, 133.9, 133.0, 129.9, 128.9, 128.9, 128.4, 128.0, 118.2; LRMS (ESI) m/z calcd for $C_{14}H_9ClNO_2$ $[M + H]^+$ 258.0, found 258.0.

6-Fluoro-2-phenyl-4H-3,1-benzoxazin-4-one (2r):¹⁷ yield 84% (101 mg); white solid; mp 130–131 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 8.27 (d, $J = 7.5$ Hz, 2H), 7.87 (dd, $J = 7.5, 2.2$ Hz, 1H), 7.73–7.67 (m, 1H), 7.61–7.45 (m, 4H); ¹³C NMR (75 MHz, $CDCl_3$) δ 163.1, 159.8, 158.9, 158.9, 156.6, 156.6, 143.6, 143.6, 132.8, 130.0, 129.7, 129.6, 128.9, 128.3, 125.0, 124.7, 118.4, 118.3, 114.2, 113.8; LRMS (ESI) m/z calcd for $C_{14}H_9FNO_2$ $[M + H]^+$ 242.1, found 242.1.

6,7-Dimethoxy-2-phenyl-4H-3,1-benzoxazin-4-one (2s):^{17f} yield 79% (112 mg); white solid; mp 197–198 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 8.23 (d, $J = 7.3$ Hz, 2H), 7.58–7.40 (m, 4H), 7.06 (s, 1H), 4.01 (s, 3H), 3.97 (s, 3H); ¹³C NMR (101 MHz, $CDCl_3$) δ 159.4, 156.6, 156.4, 149.6, 143.3, 132.3, 130.4, 128.7, 128.0, 109.6, 108.1, 107.5, 56.6, 56.4; LRMS (ESI) m/z calcd for $C_{16}H_{14}NO_4$ $[M + H]^+$ 284.1, found 284.1.

8-Methyl-2-phenyl-4H-3,1-benzoxazin-4-one (2t): yield 85% (101 mg); white solid; mp 121–123 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 8.26 (d, $J = 6.6$ Hz, 2H), 8.01 (d, $J = 7.1$ Hz, 1H), 7.59 (d, $J = 6.4$ Hz, 1H), 7.51 (d, $J = 6.0$ Hz, 1H), 7.46 (d, $J = 6.5$ Hz, 2H), 7.35–7.29 (m, 1H), 2.59 (s, 3H); ¹³C NMR (101 MHz, $CDCl_3$) δ 160.1, 155.8, 145.2, 137.3, 136.2, 132.4, 130.5, 128.7, 128.2, 127.7, 126.1, 116.9, 17.1; HRMS (ESI) m/z calcd for $C_{15}H_{12}NO_2$ $[M + H]^+$ 238.0863, found 238.0869.

7-Fluoro-2-phenyl-4H-3,1-benzoxazin-4-one (2u):^{17g} yield 61% (74 mg); white solid; mp 150–152 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 8.35–8.21 (m, 3H), 7.62–7.56 (m, 1H), 7.55–7.48 (m, 2H), 7.34 (d, $J = 9.1$ Hz, 1H), 7.22 (t, $J = 8.4$ Hz, 1H); ¹³C NMR (75 MHz, $CDCl_3$) δ 169.6, 166.2, 158.7, 158.4, 149.7, 149.5, 133.1, 131.6, 131.4, 129.9, 128.9, 128.6, 116.9, 116.6, 113.7, 113.6, 113.5, 113.2; LRMS (ESI) m/z calcd for $C_{14}H_9FNO_2$ $[M + H]^+$ 242.1, found 242.1.

6-Methoxy-2-phenyl-4H-3,1-benzoxazin-4-one (2v):¹⁷ yield 60% (76 mg); white solid; mp 137–139 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 8.25 (d, $J = 7.3$ Hz, 2H), 7.62–7.56 (m, 2H), 7.55–7.44 (m, 3H), 7.36 (d, $J = 7.3$ Hz, 1H), 3.90 (s, 3H); ¹³C NMR (101 MHz, $CDCl_3$) δ 159.9, 159.3, 155.3, 141.2, 132.3, 130.4, 128.8, 128.8, 128.0, 126.0, 117.8, 108.7, 56.0; LRMS (ESI) m/z calcd for $C_{15}H_{12}NO_3$ $[M + H]^+$ 254.1, found 254.1.

6,7-(Methylenedioxy)-2-phenyl-4H-3,1-benzoxazin-4-one (2w):^{16f} yield 53% (71 mg); yellow solid; mp 185–187 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 8.25 (d, $J = 7.4$ Hz, 2H), 7.59–7.44 (m, 4H), 7.05 (s, 1H), 6.13 (s, 2H); ¹³C NMR (101 MHz, $CDCl_3$) δ 159.3, 156.5, 155.0, 148.2, 145.1, 132.5, 130.3, 128.8, 128.2, 111.3, 106.3, 105.6, 102.8; LRMS (ESI) m/z calcd for $C_{15}H_{10}NO_4$ $[M + H]^+$ 268.1, found 268.1.

6-Methyl-2-phenyl-4H-3,1-benzoxazin-4-one (2x):¹⁷ yield 65% (77 mg); white solid; mp 136–138 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 8.30–8.22 (m, 2H), 7.99 (d, $J = 11.2$ Hz, 1H), 7.63–7.40 (m, 5H), 2.44 (s, 3H); ¹³C NMR (101 MHz, $CDCl_3$) δ 159.8, 156.4, 144.8, 138.7, 137.8, 132.4, 130.4, 128.8, 128.2, 127.0, 116.7, 21.4; LRMS (ESI) m/z calcd for $C_{15}H_{12}NO_2$ $[M + H]^+$ 238.1, found 238.1.

2-Phenyl-4H-naphtho[1,2-d][1,3]oxazin-4-one (2y):¹⁷ yield 78% (107 mg); yellow solid; mp 180–182 °C; ¹H NMR (400 MHz, $CDCl_3$) δ 8.91 (d, $J = 7.7$ Hz, 1H), 8.37 (d, $J = 7.5$ Hz, 2H), 8.03 (d, $J = 8.6$ Hz, 1H), 7.85–7.75 (m, 2H), 7.71–7.62 (m, 2H), 7.60–7.48 (m, 3H); ¹³C NMR (101 MHz, $CDCl_3$) δ 159.9, 158.0, 146.0, 137.2, 132.8, 130.4, 130.2, 129.2, 128.8, 128.5, 128.4, 128.0, 127.4, 125.4, 122.4, 112.9; LRMS (ESI) m/z calcd for $C_{18}H_{12}NO_2$ $[M + H]^+$ 274.1, found 274.1.

■ ASSOCIATED CONTENT

📄 Supporting Information

Copies of ¹H and ¹³C NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org/>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: zhuyongming@suda.edu.cn.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We gratefully acknowledge the financial support by PAPD (A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions) and NSFC (National Natural Science Foundation of China, 21172162).

■ REFERENCES

- (1) Hedstrom, L.; Moorman, A. R.; Dobbs, J.; Abeles, R. H. *Biochemistry* **1984**, *23*, 1753.
- (2) Jarvest, R. L.; Parratt, M. J.; Debouck, C. M.; Gorniak, J. G.; John Jennings, L.; Serafinowska, H. T.; Strickler, J. E. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 2463.
- (3) (a) Stein, R. L.; Strimpler, A. M.; Viscarello, B. R.; Wildonger, R. A.; Mauger, R. C.; Trainor, D. A. *Biochemistry* **1987**, *26*, 4126. (b) Krantz, A.; Spencer, R. W.; Tam, T. F.; Liak, T. J.; Copp, L. J.; Thomas, E. M.; Rafferty, S. P. *J. Med. Chem.* **1990**, *33*, 464.
- (4) Gütschow, M.; Neumann, U. *Bioorg. Med. Chem.* **1997**, *5*, 1935.
- (5) Hays, S. J.; Caprathe, B. W.; Gilmore, J. L.; Amin, N.; Emmerling, M. R.; Michael, W.; Nadimpali, R.; Nath, R.; Raser, K. J.; Stafford, D.; Watson, D.; Wang, K.; Jaen, J. C. *J. Med. Chem.* **1998**, *41*, 1060.
- (6) Neumann, U.; Schechter, N. M.; Gütschow, M. *Bioorg. Med. Chem.* **2001**, *9*, 947.
- (7) Fenton, G.; Newto, C. G.; Wyman, B. M.; Bagge, P.; Dron, D. I.; Riddell, D.; Jones, G. D. *J. Med. Chem.* **1989**, *32*, 265.
- (8) (a) Halford, J. C. *Curr. Opin. Invest. Drugs* **2006**, *7*, 312. (b) Kopelman, P.; Bryson, A.; Hickling, R.; Rissanen, A.; Rossner, S.; Toubro, S.; Valensi, P. *Int. J. Obes.* **2007**, *31*, 494. (c) Yamada, Y.; Kato, T.; Ogino, H.; Ashina, S.; Kato, K. *Horm. Metab. Res.* **2008**, *40*, 539. (d) Padwal, R. *Curr. Opin. Invest. Drugs* **2008**, *9*, 414.
- (9) (a) Errede, L. A.; Oien, H. T.; Yarian, D. R. *J. Org. Chem.* **1977**, *42*, 12. (b) Clémence, F.; LeMartret, O.; Collard, J. J. *Heterocycl. Chem.* **1984**, *21*, 1345. (c) Habib, O. M.; Moawad, E. B.; Girges, M. M.; El-Shafei, A. M. *Boll. Chim. Farm.* **1995**, *134*, 503. (d) Ibrahim, S. S.; Abdel-Halim, A. M.; Gabr, Y.; El-Edfawy, S.; Abdel-Rahman, R. J. *Chem. Res., Synop.* **1997**, 154. (e) Bratt, K.; Sunnerheim, K.; Bryngelsson, S.; Fagerlund, A.; Engman, L.; Andersson, R. E.; Dimberg, L. H. *J. Agric. Food Chem.* **2003**, *51*, 594. (f) Eissa, A. M. F.; El-Sayed, R. J. *Heterocycl. Chem.* **2006**, *43*, 1161. (g) Kostakis, I. K.; Elomri, A.; Seguin, E.; Iannelli, M.; Besson, T. *Tetrahedron Lett.* **2007**, *48*, 6609. (h) Kumar, S.; Kaur, H.; Singh, I.; Sharma, M.; Vishwakarma, P.; Saxena, K. K.; Kumar, A. *World J. Chem.* **2009**, *4*, 195. (i) Li, X.; Huo, X.; Li, J.; She, X.; Pan, X. *Chin. J. Chem.* **2009**, *27*, 1379. (j) Gupta, A.; Kashaw, S. K.; Jain, N.; Rajak, H.; Soni, A.; Stables, J. P. *Med. Chem. Res.* **2011**, *20*, 1638.
- (10) For reviews on benzoxazinones synthesis, see: (a) Coppola, G. M. *J. Heterocycl. Chem.* **1999**, *36*, 563. (b) Coppola, G. M. *J. Heterocycl. Chem.* **2000**, *37*, 1369.
- (11) (a) Beck, J. R.; Yahner, J. A. *J. Org. Chem.* **1973**, *38*, 2450. (b) Zentmyer, D. T.; Wagner, E. C. *J. Org. Chem.* **1949**, *14*, 967. (c) Papadopoulos, E. P.; Torres, C. D. *Heterocycles* **1982**, *19*, 1039. (d) Rose, U. J. *Heterocycl. Chem.* **1991**, *28*, 2005. (e) Clayden, J.; Vallverdú, L.; Helliwell, M. *Org. Biomol. Chem.* **2006**, *4*, 2106. (f) Nayak, M. K.; Kim, B. H.; Kwon, J. E.; Park, S.; Seo, J.; Chung, J. W.; Park, S. Y. *Chem.—Eur. J.* **2010**, *16*, 7437. (g) Manivannan, E.; Chaturvedi, S. C. *Bioorg. Med. Chem.* **2011**, *19*, 4520.

(12) (a) Bristow, T. H. C.; Foster, H. E.; Hooper, M. J. *Chem. Soc., Chem. Commun.* **1974**, 677. (b) Richman, R. J.; Hassner, A. J. *Org. Chem.* **1968**, 33, 2548. (c) Adam, J.; Winkler, T. *Helv. Chim. Acta* **1984**, 67, 2186. (d) Kumar, R. A.; Maheswari, C. U.; Ghantasala, S.; Jyothi, C.; Reddy, K. R. *Adv. Synth. Catal.* **2011**, 353, 401.

(13) (a) Crabtree, H. E.; Smalley, R. K.; Suschitzky, H. J. *Chem. Soc. C* **1968**, 2730. (b) Smalley, R. K.; Suschitzky, H. *Tetrahedron Lett.* **1966**, 29, 3465. (c) Archer, J. G.; Barker, A. J.; Smalley, R. K. *J. Chem. Soc., Perkin Trans. 1* **1973**, 1169.

(14) Molina, P.; Conesa, C.; Velasco, M. D. *Tetrahedron Lett.* **1993**, 34, 175.

(15) Gütschow, M. J. *Org. Chem.* **1999**, 64, 5109.

(16) (a) Larock, R. C.; Fellows, C. A. *J. Org. Chem.* **1980**, 45, 363. (b) Cacchi, S.; Fabrizi, G.; Marinelli, F. *Synlett* **1996**, 997. (c) Larksarp, C.; Alper, H. *Org. Lett.* **1999**, 1, 1619. (d) Salvadori, J.; Balducci, E.; Zaza, S.; Petricci, E.; Taddei, M. *J. Org. Chem.* **2010**, 75, 1841. (e) Houlden, C. E.; Hutchby, M.; Bailey, C. D.; Ford, J. G.; Tyler, S. N. G.; Gagne, M. R.; Loyd-Jones, G. C.; Booker-Milburn, K. I. *Angew. Chem.* **2009**, 121, 1862. (f) Giri, R.; Lam, J. K.; Yu, J. Q. *J. Am. Chem. Soc.* **2010**, 132, 686. (g) Ács, P.; Mueller, E.; Rangits, G.; Lorand, T.; Kollar, L. *Tetrahedron* **2006**, 62, 12051. (h) Wu, X.-F.; Schranck, J.; Neumann, H.; Beller, M. *Chem.—Eur. J.* **2011**, 17, 12246. (i) Wu, X.-F.; Neumann, H.; Beller, M. *Chem.—Eur. J.* **2012**, 18, 12599. (j) Xue, L.; Shi, L.; Han, Y.; Xia, C.; Huynh, H. V.; Li, F. *Dalton Trans.* **2011**, 40, 7632.

(17) Liu, Q.; Chen, P.; Liu, G. *ACS Catal.* **2013**, 3, 178.

(18) Ge, Z.-Y.; Fei, X.-D.; Tang, T.; Zhu, Y.-M.; Shen, J.-K. *J. Org. Chem.* **2012**, 77, 5736.

(19) Li, X.; Fang, Y.; Deng, P.; Hu, J.; Li, T.; Feng, W.; Yuan, L. *Org. Lett.* **2011**, 13, 4628.